Parkinson's disease: Changes in apoptosis-related factors suggesting possible gene therapy

Journal of Neural Transmission

Volumn 109, Issue 5-6, 2002, Pages 731-745

  Nagatsu, T ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cytokines; Gene therapy; Neurotrophins; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYL 1,2,3,4 TETRAHYDROPYRIDINE; APOMORPHINE; APOPTOSIS INDUCING FACTOR; AROMATIC LEVO AMINO ACID DECARBOXYLASE; BETA 2 MICROGLOBULIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 2; DOPAMINE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EPIDERMAL GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; NERVE GROWTH FACTOR; NEUROTROPHIN; OXIDOPAMINE; PROTEIN BCL 2; PYRIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; SELEGILINE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BRAIN LEVEL; CORPUS STRIATUM; CYTOKINE RELEASE; DOPAMINERGIC NERVE CELL; ENZYME SYNTHESIS; GENE THERAPY; HUMAN; IMMUNE RESPONSE; LEUKOCYTE COUNT; NERVE DEGENERATION; NEUROPROTECTION; NEUTROPHIL; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ANIMALS; ANTIBODY FORMATION; APOPTOSIS; BRAIN; CYTOKINES; GENE THERAPY; HUMANS; NERVE GROWTH FACTORS; PARKINSON DISEASE;

EID: 0036324240     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020200061     Document Type: Article

References (91)

1. Multiple subcellular localization of bcl-2: Detection in unclear outer membrane, endoplastic reticulum membrane and mitochondrial membranes
2. Apoptosis induced by an endogenous neurotoxin, N-methyl (R) salsolinol, is mediated by activation of caspase 3
3. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease
4. Immune function of microglia
5. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease
6. TNFα contributes to the death of NGF-dependent neurons during development
7. Experimental models of Parkinson's disease
8. Inflammatory cytokines within the central nervous system: Source, function and mechanisms of action
9. Chronic systemic pesticide exposure reproduces features of Parkinson's disease
10. Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model
11. Interleukin 1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's patients
12. Immunocytochemical analysis of tumor necrosis factor and its receptor in Parkinson's disease
13. Molecular cloning of the interleukin-1β converting enzyme
14. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule
15. A one-hit model of cell death in inherited neuronal degenerations
16. Glial cell line-derived neurotrophic factor (GDNF) gene therapy protects dopaminergic terminals from degeneration
17. Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease
18. Pathogenesis and preclinical course of Parkinson's disease
19. Concentrations of neopterin and biopterin in the cerebrospinal fluid from patients with Parkinson's disease
20. Functional recovery in parkinsonian monkeys treated with GDNF
21. MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson's disease: Neuroprotective strategies
22. Inhibition of JNK by over expression of the JNK binding domain of JIP-1 prevents apoptosis in sympathetic neurons
23. Caspase-3: A vulnerability factor and afinal effector in the apoptotic cell death of dopaminergic neurons in Parkinson's disease
24. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
25. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis
26. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
27. Bcl-2 functions in an antioxidant pathway to prevent apoptosis
28. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin
29. Cell death mechanism in Parkinson's disease
30. Bcl-2 inhibition of neural death: Decreased generation of reactive oxygen species
31. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
32. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease
33. Involvement of α-synuclein in Parkinson's disease and other neurodegeneartive disorders
34. ICE-like proteases in apoptosis
35. β-Carbolinium cations, endogenous MPP+ analogs in the lumbar cerebrospinal fluid of parkinsonian patients
36. Interleukin 1β promotes repair of the CNS
37. The inflammatory response system of brain, implications for therapy of Alzheimer and other neurodegenerative diseases
38. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's disease and Alzheimer's disease brain
39. Tumor necrosis factor α is toxic to embryonic mesencephalic dopamine neurons
40. Failure of the ubiquitin-proteasome system in Parkinson's disease
41. Mitochondrial dysfunction in Parkinson's disease
42. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease
43. Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in Parkinsonian brain
44. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients
45. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients
46. Transforming growth factor-β1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease
47. Brain β2-microglobulin levels are elevated in the striatum in Parkinson's disease
48. Interleukin (IL)-1β, Il-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease
49. bcl-2 Protein is increased in the brain from parkinsonian patients
50. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain
51. The soluble form of Fas molecule is elevated in parkinsonian brain tissues
52. Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatum
53. Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-α induction
54. Brain derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease
55. Neurotrophins and cytokines in Parkinson's disease
56. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain
57. Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506
58. Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains
59. Apoptosis by death factor
60. The Fas death factor
61. Isoquinoline neurotoxins and Parkinson's disease
62. Amine-related neurotoxins in Parkinson's disease: Past, present, and future
63. Cytokines in Parkinson's disease
64. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin
65. Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis
66. Biosynthesis of tetrahydrobiopterin in Parkinsonian human brain
67. Cytokines in Parkinson's disease
68. Neopterin and cytokines in hereditary dystonia and Parkinson's disease
69. Cytokines in Parkinson's disease
70. Changes in cytokines and neurotrophins in Parkinson's disease
71. Dopamine-derived endogenous 1(R), 2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rats: Biochemical, pathological and behavioral studies
72. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons
73. Immunophilin ligands: Possible neuroprotective agents
74. Combating Parkinson's disease-step three
75. Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes
76. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
77. Social controls on cell survival and cell death
78. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo
79. Cytokines in the central nervous system: Regulatory roles of neuronal function, cell death and repair
80. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease
81. Nerve growth factor prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced cell death via the Akt pathway by suppressing caspase-3-like activity using PC12 cells: Relevance to the therapeutical application for Parkinson's disease
82. Familial Parkinson gene product, parkin, is a ubiquitin-protein ligase
83. Ubiquitination of a new form of α-synuclein by parkin from human brain: Implications for Parkinson's disease
84. Parkin is linked to the ubiquitin pathway
85. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotididyl transferase labelling and acridine orange staining
86. Loss of basic fibroblast growth factor in substantia nigra neurons in Parkinson's disease
87. TGF β1 and TGF β2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid
88. Cell death and apoptosis regulating proteins in Parkinson's disease - A cautionary note
89. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease
90. Ribozyme-mediated inhibition of caspase-3 activity reduces apoptosis induced by 6-hydroxydopamine in PC12 cells
91. Apoptosis in the central nervous system